Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.63 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873704 | 0.94 | MCHR1 (0.62) | MCHR1RAB9ANPC1MEN1MAPT | |
| SCHEMBL5873534 | 0.86 | MCHR1 (0.56) | MCHR1RAB9ANPC1MEN1MAPT | |
| SCHEMBL5873563 | 0.86 | MCHR1 (0.65) | MCHR1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL5873615 | 0.84 | MCHR1 (0.61) | MCHR1EPHX2 | |
| SCHEMBL5873484 | 0.83 | MCHR1 (0.79) | MCHR1 | |
| SCHEMBL5873617 | 0.83 | MCHR1 (0.56) | MCHR1RAB9ANPC1MAPT | |
| SCHEMBL5873621 | 0.83 | MCHR1 (0.56) | MCHR1RAB9ANPC1MAPT | |
| SCHEMBL6560080 | 0.82 | MCHR1 (0.54) | MCHR1RAB9ANPC1MEN1MAPT | |
| SCHEMBL5873550 | 0.82 | MCHR1 (0.61) | MCHR1 | |
| SCHEMBL5873765 | 0.81 | MCHR1 (0.54) | MCHR1RAB9ANPC1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084156-B2 | 2-Aminoquinoline compounds | MERCK & CO., INC. (US) | 2006-08-01 | — | — | US | claimed |
| US-20050026915-A1 | 2-Aminoquinoline compounds | MERCK SHARP & DOHME CORP. | 2005-02-03 | — | — | US | claimed |
| EP-1450801-A2 | 2-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026915-A1 | 2-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | MCHR1 1/4885RAB9A 1226/4885NPC1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.